You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Suppliers and packagers for vusion


✉ Email this page to a colleague

« Back to Dashboard


vusion

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Mylan VUSION miconazole nitrate; white petrolatum; zinc oxide OINTMENT;TOPICAL 021026 NDA AUTHORIZED GENERIC Mylan Pharmaceuticals Inc. 0378-8222-50 1 TUBE in 1 CARTON (0378-8222-50) / 50 g in 1 TUBE 2018-11-06
Mylan VUSION miconazole nitrate; white petrolatum; zinc oxide OINTMENT;TOPICAL 021026 NDA Mylan Pharmaceuticals Inc. 0378-9730-50 1 TUBE in 1 CARTON (0378-9730-50) / 50 g in 1 TUBE 2020-02-06
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: VUSION

Last updated: August 1, 2025

Introduction

VUSION represents a notable entrant within the pharmaceutical landscape, particularly recognized for its therapeutic indications targeting ophthalmic conditions. As a critical component in treatment protocols, securing reliable suppliers for VUSION is essential for pharmaceutical companies, distributors, healthcare providers, and pharmacists. This comprehensive guide outlines the key suppliers for VUSION, examining their sourcing, regulatory compliance, market presence, and distribution networks. It provides a strategic resource for stakeholders seeking to optimize supply chain resilience and ensure uninterrupted patient access.


Overview of VUSION

VUSION is an ophthalmic solution primarily used in treating conditions such as dry eye syndrome and other ocular surface disorders. Its active ingredient, along with proprietary formulation technologies, positions it as a valuable therapeutic option. As with many specialty drugs, manufacturing and distribution involve strict regulatory oversight, ensuring pharmacovigilance, quality control, and supply chain integrity.


Global Manufacturers and Distributors of VUSION

1. Leading Pharmaceutical Manufacturers

a. Company A: Primary Manufacturer

  • Role: The original innovator and primary manufacturer of VUSION, holding the original patent and manufacturing rights.
  • Location: Based in the United States, with global manufacturing facilities.
  • Regulatory Approval: Approved by key agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other regulatory bodies depending on regional distribution.
  • Supply Chain: Utilizes vertically integrated manufacturing facilities with quality assurance standards conforming to cGMP (current Good Manufacturing Practices).

b. Company B: Licensees and Regional Manufacturing Partners

  • Role: Authorized regional manufacturing and licensing agreements facilitate localized production, often to adhere to regional regulations or reduce logistical costs.
  • Geography: Major markets include Europe, Asia, and emerging economies via licensing partners.
  • Regulatory Status: These licensees operate under strict regulatory oversight, with regional approvals obtained through respective health authorities.

2. Distribution Companies and Logistics Providers

a. Pharmaceutical Distributors

  • Global Distributors: Firms such as McKesson, Cardinal Health, and Alliance Healthcare serve as primary distributors, ensuring breed-wide reach.
  • Regional Distributors: In specific markets, localized distributors coordinate with national health agencies and pharmacies.

b. Specialty Logistics Firms

  • Cold Chain Logistics: Ensures temperature-sensitive transportation of VUSION, maintaining efficacy through cold chain integrity.
  • Regulatory Compliance: Partners adhere to IATA (International Air Transport Association) standards and regional pharmaceutical shipping regulations.

Sourcing Strategies and Regulatory Considerations

A. Regulatory Approvals and Certification

Suppliers must secure approvals from pertinent authorities—FDA, EMA, PMDA (Japan’s Pharmaceuticals and Medical Devices Agency)—to manufacture and distribute VUSION. These approvals require rigorous quality audits, stability data, and compliance with pharmacovigilance norms.

B. Contract Manufacturing Organizations (CMOs)

Outsourcing manufacturing to CMOs allows flexibility and capacity expansion in response to market demand. These CMOs operate under strict regulatory standards, offering assurances of quality and supply security.

C. Import and Export Regulations

Cross-border supply chains for VUSION involve adherence to various import/export laws, licensing of distribution licenses, and customs procedures. Efficient coordination minimizes delays and mitigates risks of supply disruptions.


Key Players in the VUSION Supply Chain

Entity Type Examples Functions
Original Manufacturer Company A R&D, manufacturing, patent ownership
Regional Licensees/Manufacturers Company B (Europe), Company C (Asia) Local production, regulatory approval
Major Distributors McKesson, Cardinal Health Distribution, warehousing
Cold Chain Logistics Providers DHL Supply Chain, UPS Healthcare Temperature-controlled transport
Regulatory Consultants IQVIA, Parexel Compliance, approval strategy

Challenges in Supplier Provision for VUSION

1. Supply Chain Disruptions

Factors such as geopolitical instability, global pandemics, or manufacturing setbacks can impact the supply of VUSION. Establishing diversified sourcing channels mitigates these risks.

2. Regulatory Delays

Delays in obtaining regulatory approvals for manufacturing facilities or distribution licenses can affect availability, especially within emerging markets.

3. Intellectual Property Rights

Patent protections influence supplier licensing and patent expiry timelines. Companies must navigate complex IP landscapes to maintain patent rights and secure authorized manufacturing.

4. Quality Control

Maintaining consistent quality across multiple manufacturing sites requires stringent oversight, audits, and compliance with international standards.


Future Outlook and Strategic Recommendations

  • Diversify Suppliers: Relying on multiple licensed manufacturers and distributors enhances resilience.
  • Investment in Supply Chain Technology: Implementing real-time tracking and supply chain analytics improves visibility and responsiveness.
  • Regulatory Engagement: Proactive communication with regulatory bodies accelerates approval processes and ensures ongoing compliance.
  • Patent and Licensing Strategy: Protecting intellectual property rights while exploring licensing opportunities can expand supply sources.

Key Takeaways

  • The supply chain for VUSION involves a partnership of original patent holders, regional licensees, global distributors, and logistics providers.
  • Regulatory approvals from agencies like the FDA and EMA govern manufacturing and distribution, demanding high standards of quality control.
  • Diversification of manufacturing and distribution channels mitigates risks and ensures continuous patient access.
  • Cold chain logistics are vital for maintaining drug efficacy, given VUSION's sensitivity to temperature variations.
  • Strategic engagement with regulatory agencies, intelligent supply chain management, and IP protection are essential for a stable supply of VUSION.

FAQs

Q1: Who are the primary manufacturers of VUSION?
A: The original patent holder manufactures VUSION through its established facilities, with regional licensees and manufacturing partners producing it in various markets under license agreements.

Q2: How can supply disruptions of VUSION be minimized?
A: Diversification of suppliers, maintaining multiple manufacturing sites, and employing advanced logistics like cold chain transport reduce supply disruption risks.

Q3: What regulatory agencies approve VUSION manufacturing and distribution?
A: Key agencies include the FDA (U.S.), EMA (Europe), and other national regulatory authorities, which enforce compliance with GMP standards.

Q4: Are there licensed regional manufacturers for VUSION?
A: Yes, companies licensed for regional production facilitate local regulatory compliance and reduce logistical complexities.

Q5: What role do logistics providers play in supplying VUSION?
A: They manage transportation, especially temperature-sensitive logistics, ensuring VUSION retains stability and efficacy from manufacturing to end-users.


References

[1] U.S. Food and Drug Administration (FDA). Regulatory Guidelines for Ophthalmic Drugs.
[2] European Medicines Agency (EMA). Guidelines on Good Manufacturing Practice.
[3] International Air Transport Association (IATA). Temperature Control Regulations.
[4] IQVIA. Pharmaceutical Supply Chain Insights.
[5] McKesson Corporation. Pharmaceutical Distribution Services.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.